Kardigan Secures $300 Million Series A Funding to Revolutionize Cardiovascular Drug Development

Kardigan secures $300 million in Series A funding to develop targeted treatments for cardiovascular diseases

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here